Positive Results from CHAPTER-1 Phase 2 Study of Deucrictiba

ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today

Related Keywords

Washington , United States , Russia , Ukraine , Switzerland , Israel , Canada , United Kingdom , American , Peng Lu , Joan Mendivil , Marca Riedl , American Academy Of Allergy , European Union , Waltere Washington Convention Center , Wave Ii Disease Specific Program , Exchange Commission , American Academy , Scientific Meeting , Clinical Immunology , Oral Deucrictibant , Hereditary Angioedema Attacks , Chief Medical Officer , Treat All , Patient Satisfaction , On Demand Treatment , Specific Program , Statement Regarding Forward Looking , Annual Report , Maggie Beller Executive Director , Region ,